{"id":"W4387962267","doi":"10.1200/op.2023.19.11_suppl.332","title":"Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.","year":2023,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Placebo; Endometrial cancer; Internal medicine; Population; Carboplatin; Quality of life (healthcare); Urology; Progression-free survival; Paclitaxel; Clinical endpoint; Gastroenterology; Randomized controlled trial; Oncology; Cancer; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001177885,0.0007160984,0.002011212,0.0009354817,0.0001945297,0.00005976949,0.0002909867,0.000317581,0.0001447522],"category_scores_gemma":[0.003859898,0.0003631976,0.0001357953,0.005589441,0.0002355236,0.0006024866,0.0001132537,0.001207056,0.00002544261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00285554,"about_ca_system_score_gemma":0.001898328,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005004534,"about_ca_topic_score_gemma":0.007574763,"domain_scores_codex":[0.9938739,0.001122908,0.001383605,0.00109524,0.001513431,0.001010935],"domain_scores_gemma":[0.9899294,0.006972958,0.001427801,0.0007991871,0.0005730485,0.0002976555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6923232,0.006487958,0.244815,0.0001161271,0.001172235,0.002363215,0.002323828,0.0002062503,0.00002832229,0.000008806914,0.0003620239,0.04979303],"study_design_scores_gemma":[0.5467871,0.0578749,0.3658615,0.0004903001,0.001907509,0.0001404057,0.004427326,0.00004494721,0.00009251876,0.000006885712,0.02167645,0.0006901393],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815485,0.00033905,0.000004652799,0.003438698,0.0006622644,0.008370258,0.0001249481,0.0001762456,0.005335424],"genre_scores_gemma":[0.9921093,0.0004326736,0.0009570583,0.002033893,0.0001886785,0.003263878,0.0005453136,0.00009838522,0.0003708366],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1455361,"threshold_uncertainty_score":0.999882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05341484935085666,"score_gpt":0.3653009875459587,"score_spread":0.3118861381951021,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}